557 related articles for article (PubMed ID: 23907440)
1. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy in Brain Metastases: Ready for Primetime?
Venur VA; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714
[TBL] [Abstract][Full Text] [Related]
3. Current Treatment Options for Breast Cancer Brain Metastases.
Raghunath A; Desai K; Ahluwalia MS
Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
5. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
6. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
8. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
Liu K; Jiang G; Zhang A; Li Z; Jia J
BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
[TBL] [Abstract][Full Text] [Related]
9. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
Long GV; Margolin KA
Am Soc Clin Oncol Educ Book; 2013; ():393-8. PubMed ID: 23714558
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Ahluwalia MS; Becker K; Levy BP
Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
[TBL] [Abstract][Full Text] [Related]
14. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
15. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
[TBL] [Abstract][Full Text] [Related]
16. Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Lin CH; Hsu KH; Chang SN; Tsou HK; Sheehan J; Sheu ML; Pan HC
Radiat Oncol; 2015 Jun; 10():127. PubMed ID: 26048754
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
18. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain.
Steiger HJ; Vollmer K; Rogers S; Schwyzer L
Neurosurg Rev; 2022 Oct; 45(5):3119-3138. PubMed ID: 35902427
[TBL] [Abstract][Full Text] [Related]
19. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]